Business
Medicenna Therapeutics Reports Fiscal Year 2025 Financial Results and Operational Highlights
Updated cash guidance provides runway into at least mid-2026 MDNA11 Phase 1/2 clinical tr...
About this update from Medicenna Therapeutics Corp.
[{"type":"text","content":"Medicenna Therapeutics Reports Fiscal Year 2025 Financial Results and Operational Highlights\n\n\n\n\n Updated cash guidance provides runway into at least mid-2026\n \n\n\n\n MDNA11 Phase 1/2 clinical trial on track for data readouts in second half of the year as a single agent and in combination with KEYTRUDA\n \n ®\n \n at medical conferences and a planned KOL event\n \n\n\n\n MDNA11 continues to exhibit compelling deep and durable anti-tumor activity in difficult-to-treat solid tumors with best-in-class potential relative to competing IL-2 programs\n \n\n\n\n Results presented at the 2025 AACR showed response rates in the 30-50% range in various tumor cohorts amongst high dose patients with tumor types being enrolled in Phase 2\n \n\n\n\n Three cancer patients treated with MDNA11 remain tumor free since achieving complete resolution of all target and non-target lesions\n \n\n\n\n MDNA11 Phase 2b development plan to be solidified by end of calendar year, including evaluation of strategies for accelerated approval\n \n\n\n\n MDNA113, the Company’s first-in-class masked and tumor-targeted PD-1 x IL-2 bi-specific, is advancing to non-human primate studies in the second half of 2025\n \n\n\n TORONTO and HOUSTON, June 26, 2025 (GLOBE NEWSWIRE) -- Medicenna Therapeutics Corp. (“Medicenna” or the “Company”) (TSX: MDNA, OTCQX: MDNAF), a clinical-stage immunotherapy company focused on the development of Superkines targeting cancer, autoimmune, and inflammatory diseases, today reported financial results and corporate highlights for the fiscal year ended March 31, 2025, as well as anticipated corporate milestones.\n \n\n “We are delighted to announce that the first MDNA11 monotherapy responder, a pancreatic cancer patient who had failed multiple lines of therapy including a checkpoint inhibitor, continues to be in remission for at least 18 months without any further treatment. Complete and partial responses in nine other patients in mono- and combination arms demonstrates best-in-class potential of MDNA11 amongst competing IL-2 programs,” said Fahar Merchant, Ph.D., President and CEO of Medicenna. “We plan to complete enrollment in the Phase 1/2 ABILITY-1 trial and report top-line data from both monotherapy and combination arms before the end of this year. Encour...